Selective serotonin reuptake inhibitors for children and adolescents.

被引：16

作者：

Kastelic E.A. ^{[1
]}

Labellarte M.J. ^{[1
]}

Riddle M.A. ^{[1
]}

机构：

[1] Division of Child and Adolescent Psychiatry, Department of Psychiatry, Johns Hopkins Medical Institutions, CMSC 346, 600 North Wolfe Street, Baltimore, 21287, MD

来源：

Current Psychiatry Reports | 2000年 / 2卷 / 2期

关键词：

Fluoxetine; Paroxetine; Sertraline; Selective Serotonin Reuptake Inhibitor; Fluvoxamine;

D O I：

10.1007/s11920-000-0055-x

中图分类号：

学科分类号：

摘要：

The controlled studies of selective serotonin reuptake inhibitors (SSRIs) in pediatric psychopharmacology research lag behind the controlled studies of SSRIs in adults. As a result, widespread use of SSRIs in the treatment of child and adolescent psychiatric disorders is in stark contrast to the paucity of research data. Recent changes in the research climate (including support from the National Institute of Mental Health, the Food and Drug Administration, and industry) have encouraged well-designed SSRI studies in pediatric psychopharmacology, and will ultimately provide needed information to guide treatment. This paper reviews the best available data from pediatric SSRI trials, including 10 double-blind placebo-controlled trials, and two abstracts of open-label continuation studies of SSRIs associated with large pediatric efficacy studies. Adverse events (AEs) of SSRIs in children and adolescents are discussed in reference to available pediatric studies. Recent pharmacokinetic studies of SSRIs in children and adolescents are reviewed. Future SSRI research strategies are also discussed.

引用

页码：117 / 123

页数：6

共 50 条

[31] Selective serotonin reuptake inhibitors in the treatment of social phobia: The emerging gold standard [J].

Van Ameringen M. ;

Mancini C. ;

Oakman J.M. ;

Farvolden P. .

CNS Drugs, 1999, 11 (4) :307-315

[32] Selective Serotonin Reuptake Inhibitors (SSRIs): Therapeutic Drug Monitoring and Pharmacological Interactions [J].

Mandrioli, R. ;

Mercolini, L. ;

Saracino, M. A. ;

Raggi, M. A. .

CURRENT MEDICINAL CHEMISTRY, 2012, 19 (12) :1846-1863

[33] Selective Serotonin Reuptake Inhibitors (SSRIs) and Hyperprolactinemia: Analysis of the French Pharmacovigilance Database [J].

Oger, F. ;

Buire, A. C. ;

Trenque, T. .

DRUG SAFETY, 2008, 31 (10) :932-932

[34] Selective serotonin reuptake inhibitors for fibromyalgia syndrome [J].

Walitt, Brian ;

Urrutia, Gerard ;

Betina Nishishinya, Maria ;

Cantrell, Sarah E. ;

Haeuser, Winfried .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (06)

[35] Selective serotonin reuptake inhibitors for migraine prophylaxis [J].

Landy, S ;

McGinnis, J ;

Curlin, D ;

Laizure, SC .

HEADACHE, 1999, 39 (01) :28-32

[36] Interactions of Selective Serotonin Reuptake Inhibitors with β-Amyloid [J].

Tin, Gary ;

Mohamed, Tarek ;

Shakeri, Arash ;

Pham, Amy Trinh ;

Rao, Praveen P. N. .

ACS CHEMICAL NEUROSCIENCE, 2019, 10 (01) :226-234

[37] Overdose Risk with Selective Serotonin Reuptake Inhibitors [J].

Chris Muldoon .

Drugs, 1999, 58 :1205-1206

[38] Selective serotonin Reuptake Inhibitors (SSRIs) and Hyperprolactinemia: Analysis of the French Pharmacovigilance Database [J].

F. Oger ;

A. C. Buire ;

T. Trenque .

Drug Safety, 2008, 31 :885-885

[39] Selective Serotonin Reuptake Inhibitors for Late-Life DepressionA Comparative Review [J].

LalithKumar K. Solai ;

Benoit H. Mulsant ;

Bruce G. Pollock .

Drugs & Aging, 2001, 18 :355-368

[40] Block of volume-regulated anion channels by selective serotonin reuptake inhibitors [J].

Maertens, C ;

Droogmans, G ;

Verbesselt, R ;

Nilius, B .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 366 (02) :158-165

← 1 2 3 4 5 →